These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
88 related articles for article (PubMed ID: 375622)
1. Fosfomycin therapy of experimental infections in mice. Schindler J; Langsádl L Zentralbl Bakteriol Orig A; 1979 Mar; 243(1):136-9. PubMed ID: 375622 [TBL] [Abstract][Full Text] [Related]
2. [The protective effect of phosphonic compounds (sodium-fosfomycin and arginine-fosfomycin) in experimental infections in the mouse]. Martinetto P; Valtz A; Angeretti A; Gaffodio AM; Negro Ponzi A G Ital Chemioter; 1979; 26(1-2):223-6. PubMed ID: 554813 [No Abstract] [Full Text] [Related]
3. [Importance of the cefotaxime-fosfomycin combination. Apropos of a case of meningitis due to heterogeneously resistant Staphylococcus aureus]. Tremeaux JC; Duez JM; Pechinot A; Sautreaux JL; Thierry A; Kazmierczak A Agressologie; 1983 Apr; 24(4):169-71. PubMed ID: 6314832 [No Abstract] [Full Text] [Related]
4. [Staphylococcus aureus resistant to cloxacillin: treatment with fosfomycin-rifampicin]. Wolff M; Nercelles P; Pepay K Rev Med Chil; 1984 Jul; 112(7):665-71. PubMed ID: 6569621 [No Abstract] [Full Text] [Related]
5. [Update on antibiotic therapy. 17) A combination of fosfomycin and cephalexin (cefemic cofosfolactamine)]. Di Nola F Minerva Med; 1983 May; 74(20):1217-22. PubMed ID: 6379514 [No Abstract] [Full Text] [Related]
6. [The behavior of Staphylococcus aureus responsible for hospital infections in the presence of phosphomycin activity in vitro]. Mendonca CP; Lourenço VL; Shimizu MT; Natalino PR; Anno IS Rev Saude Publica; 1975 Mar; 9(1):11-4. PubMed ID: 1145089 [No Abstract] [Full Text] [Related]
7. Coexpression of virulence and fosfomycin susceptibility in Listeria: molecular basis of an antimicrobial in vitro-in vivo paradox. Scortti M; Lacharme-Lora L; Wagner M; Chico-Calero I; Losito P; Vázquez-Boland JA Nat Med; 2006 May; 12(5):515-7. PubMed ID: 16633349 [TBL] [Abstract][Full Text] [Related]
8. Fosfomycin tromethamine as second agent for the treatment of acute, uncomplicated urinary tract infections in adult female patients in The Netherlands? Knottnerus BJ; Nys S; Ter Riet G; Donker G; Geerlings SE; Stobberingh E J Antimicrob Chemother; 2008 Aug; 62(2):356-9. PubMed ID: 18424789 [TBL] [Abstract][Full Text] [Related]
9. [Are we being threatened by multiresistant strains of Staphylococcus aureus?]. Aepfelbacher M MMW Fortschr Med; 2005 Jan; 147(4):33-5, 37. PubMed ID: 15745339 [TBL] [Abstract][Full Text] [Related]
10. Successful treatment of disseminated methicillin-resistant Staphylococcus aureus with fosfomycin, cefoperazone/sulbactam and rifampin followed by fusidic acid and rifampin. Apisarnthanarak A; Mundy LM Int J Infect Dis; 2007 May; 11(3):283-4. PubMed ID: 16876452 [No Abstract] [Full Text] [Related]
11. Experimental endocarditis and fosfomycin. Rodríguez A; Vicente MV; Olay T Drugs Exp Clin Res; 1985; 11(1):55-62. PubMed ID: 3836112 [TBL] [Abstract][Full Text] [Related]
12. Extended-spectrum beta-lactamases: will they be the new 'methicillin-resistant Staphylococcus aureus'? Hicks JA; Harris MR; Keoghane SR BJU Int; 2008 Jan; 101(2):151-2. PubMed ID: 17760887 [No Abstract] [Full Text] [Related]
13. [Fosfomycin in severe infection in neonatology]. Rossignol S; Regnier C Ann Pediatr (Paris); 1984 May; 31(5):437-44. PubMed ID: 6742722 [No Abstract] [Full Text] [Related]
14. [Current resistance in surgical infections and its development since 1970]. Kunze M; Bernasowski A; Metzel D Zentralbl Chir; 1986; 111(12):735-8. PubMed ID: 3529749 [TBL] [Abstract][Full Text] [Related]
15. CTX-M-15-producing urinary Escherichia coli O25b-ST131-phylogroup B2 has acquired resistance to fosfomycin. Oteo J; Orden B; Bautista V; Cuevas O; Arroyo M; Martínez-Ruiz R; Pérez-Vázquez M; Alcaraz M; García-Cobos S; Campos J J Antimicrob Chemother; 2009 Oct; 64(4):712-7. PubMed ID: 19671590 [TBL] [Abstract][Full Text] [Related]